تاریخچه درآمد، سود و جریان نقد از صورتهای مالی رسمی.
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
نمودارهای تعاملی و صورتهای مالی کامل ← مدل ارزشگذاری (DCF) ←
| صورت سود و زیان | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| مجموع درآمد | $1.7B | $1.4B | $1.0B | $829M | $660M | $443M | $268M | $196M | $152M | $317M | $147M | $135M | $75M | $55M | $42M | $56M | $14M | $14M | $9M | $4M | $1M |
| سود ناخالص | $1.3B | $1.1B | $856M | $637M | $521M | $362M | $224M | $150M | $142M | $285M | $113M | $106M | $53M | $49M | $41M | $56M | $13M | $13M | $8M | $4M | $1M |
| حاشیه سود ناخالص % | 78.2% | 78.1% | 84.3% | 76.8% | 78.9% | 81.6% | 83.8% | 76.8% | 93.3% | 90.2% | 77.4% | 78.3% | 69.8% | 88.6% | 97.4% | 99.5% | 92.8% | 97.7% | 96.2% | 93.7% | 55.5% |
| سود عملیاتی (EBIT) | $945M | $816M | $551M | $338M | $268M | $276M | $144M | ($68M) | ($69M) | $81M | ($83M) | ($27M) | ($63M) | ($80M) | ($54M) | ($20M) | ($54M) | ($58M) | ($50M) | ($28M) | ($16M) |
| حاشیه سود عملیاتی % | 56.8% | 58.5% | 54.3% | 40.7% | 40.5% | 62.2% | 53.9% | -34.5% | -45.6% | 25.6% | -56.7% | -20.3% | -83.7% | -146.8% | -126.7% | -35.4% | -398.2% | -427.6% | -575.5% | -740.9% | -1587.3% |
| سود خالص | $413M | $317M | $444M | $282M | $202M | $403M | $129M | ($72M) | ($80M) | $63M | ($103M) | ($32M) | ($68M) | ($83M) | ($54M) | ($20M) | ($53M) | ($58M) | ($49M) | ($24M) | ($15M) |
| حاشیه سود خالص % | 24.8% | 22.7% | 43.7% | 34.0% | 30.6% | 90.8% | 48.2% | -36.9% | -52.9% | 19.9% | -70.2% | -23.9% | -90.8% | -152.3% | -126.5% | -35.2% | -390.8% | -426.9% | -555.1% | -628.9% | -1502.6% |
| EBITDA | — | $573M | $657M | $452M | $316M | $279M | $148M | ($64M) | ($67M) | $83M | ($81M) | ($26M) | ($61M) | ($79M) | ($53M) | ($19M) | ($53M) | ($57M) | ($49M) | ($28M) | ($15M) |
| سود هر سهم (EPS) | $3.35 | $2.56 | $3.43 | $2.10 | $1.44 | $2.74 | $0.91 | $-0.50 | $-0.56 | $0.45 | $-0.81 | $-0.25 | $-0.56 | $-0.74 | $-0.48 | $-0.19 | $-0.56 | $-0.67 | $-0.61 | $-0.32 | $-0.24 |
| سهام منتشرشده (میلیون) | — | 124M | 129M | 134M | 141M | 147M | 141M | 144M | 144M | 139M | 128M | 127M | 123M | 113M | 111M | 103M | 94M | 87M | 80M | 74M | 63M |
منبع: گزارشهای عمومی شرکت (SEC). پیش از اتکا به هر رقم، آن را در SEC EDGAR بررسی کنید.
ترازنامهها، جریانهای نقدی، دادههای فصلی و نسبتهای مالی کامل در نمایشگر تعاملی HALO در دسترس است. /companies/us/HALO
اطلاعات این وبسایت صرفاً برای اهداف آموزشی و اطلاعرسانی است و توصیه سرمایهگذاری نیست. هیچ هدف قیمتی یا توصیهای منتشر نمیشود.
About TickerBase · Data methodology & sources · Privacy · Terms